Protalix BioTherapeutics
PLX
45 hedge funds and large institutions have $120M invested in Protalix BioTherapeutics in 2014 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
2% more funds holding
Funds holding: 44 → 45 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.22% less ownership
Funds ownership: 3.74% → 3.52% (-0.22%)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
25% less capital invested
Capital invested by funds: $160M → $120M (-$39.9M)
86% less call options, than puts
Call options by funds: $367K | Put options by funds: $2.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$2.12M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$454K |
| 3 |
DAM
Deltec Asset Management
New York
|
+$335K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$308K |
| 5 |
SIM
Spark Investment Management
New York
|
+$187K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Allianz Asset Management
Munich,
Germany
|
-$6.72M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.2M |
| 4 |
BCMU
BlueCrest Capital Management (UK)
St. Peter Port,
Guernsey
|
-$334K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$323K |
PLX Hedge Fund Activity: Q2 2014 in Review
45 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q2 2014, worth a combined $120M — down 25% from $160M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new PLX positions and 6 closed out — a net gain of 1 holder — while 10 added to existing stakes and 12 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $2.12M. The largest seller was Allianz Asset Management, cutting an estimated $6.72M.
- 45 institutional investors held Protalix BioTherapeutics (PLX) as of Q2 2014, up from 44 in Q1 2014.
- Funds reported $120M of Protalix BioTherapeutics stock for Q2 2014, down 25% quarter-over-quarter.
- 7 funds opened new Protalix BioTherapeutics positions in Q2 2014 and 6 closed out, a net change of +1 holder.
- The largest Protalix BioTherapeutics buyer in Q2 2014 was Baillie Gifford & Co, an estimated $2.12M added.
- The largest Protalix BioTherapeutics seller in Q2 2014 was Allianz Asset Management, an estimated $6.72M sold.
Based on aggregated 13F filings for Q2 2014.